Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Core Insights - Sensei Biotherapeutics, Inc. reported promising Phase 1/2 clinical data for SNS-101, demonstrating early signs of clinical activity in a patient population generally resistant to immunotherapy [2][5] - The company has a strong balance sheet with cash expected to fund operations into the fourth quarter of 2025 [7][9] Clinical Highlights and Milestones - SNS-101 is a conditionally active antibody targeting the immune checkpoint VISTA, which is associated with low survival rates in various cancer types [3] - The ongoing multi-center Phase 1/2 clinical trial is evaluating SNS-101 as both a monotherapy and in combination with Regeneron's PD1 inhibitor Libtayo® [4] - Initial data from the dose expansion cohorts is expected by the end of 2024, along with an end-of-Phase 1 meeting with the FDA [5] Financial Results - As of June 30, 2024, the company reported cash, cash equivalents, and marketable securities totaling $52.3 million [7] - Research and development expenses for Q2 2024 were $4.6 million, a decrease from $4.8 million in Q2 2023, primarily due to lower outside research fees [8] - General and administrative expenses decreased to $3.2 million in Q2 2024 from $5.4 million in Q2 2023, attributed to reduced costs for external professional services [9] - The net loss for Q2 2024 was $7.1 million, compared to a net loss of $9.4 million in Q2 2023 [9][11]